title: [RP 67580, a potent and selective substance P non-peptide antagonist].
abstract: The pharmacological properties of 7,7-Diphenyl-2 [1-imino-2 (2-methoxy-phenyl)-ethyl] perhydroisoindol-4-one (3 aR, 7 aR) or RP67580 are described. This compound, derived from a novel chemical family, is a potent and selective substance P (SP) antagonist, in vitro and in vivo. In vitro, it inhibited in a competitive manner (IC50 = 10 nM) 3H-SP binding in rat brain (NK1 receptors). It did not interact with the two other tachykinin receptor sites (NK2 and NK3) nor the other receptor sites tested. Moreover, RP67580 competitively antagonized the contractile activity of SP on guinea-pig ileum (pA2 = 7.16); in contrast, it was inactive in rabbit pulmonary artery and in rat portal vein tissues which contain NK2 and NK3 receptors, respectively. In vivo, in the rat, RP67580 inhibited the plasmatic extravasation induced by administration of SP (ED50 = 0.04 mg/kg i.v.) as well as that induced by antidromic stimulation of a peripheral sensory nerve (ED50 = 0.15 mg/kg i.v.). In mice and rats, RP67580, like morphine, potently blocked the nociceptive effects of phenylbenzoquinone and formalin; its antinociceptive effect does not involve opiate receptors since it was not reversed by naloxone. These results indicate that RP67580 is a particularly valuable tool for investigating the physiological and pathological role of SP.
authors.affiliation: Rhône-Poulenc Rorer, Centre de Recherches de Vitry-Alfortville, Vitry-sur-Seine.
authors.forename: C
authors.initials: C
authors.lastname: Garret
authors.forename: A
authors.initials: A
authors.lastname: Carruette
authors.forename: V
authors.initials: V
authors.lastname: Fardin
authors.forename: S
authors.initials: S
authors.lastname: Moussaoui
authors.forename: J F
authors.initials: JF
authors.lastname: Peyronel
authors.forename: J C
authors.initials: JC
authors.lastname: Blanchard
authors.forename: P M
authors.initials: PM
authors.lastname: Laduron
mesh_terms: D000700:Analgesics / Q000008:administration & dosage; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D004347:Drug Interactions; D005260:Female; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007211:Indoles / Q000494:pharmacology*; D054833:Isoindoles; D008297:Male; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D011956:Receptors, Cell Surface / Q000378:metabolism; D013373:Substance P / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015320:Tachykinins / Q000378:metabolism
chemical_list: D000700:Analgesics; D007211:Indoles; D054833:Isoindoles; D011956:Receptors, Cell Surface; D015320:Tachykinins; C071693:7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one; D013373:Substance P